Free Trial
LON:APH

Alliance Pharma (APH) Share Price, News & Analysis

Alliance Pharma logo
GBX 45
-0.30 (-0.66%)
(As of 11:49 AM ET)

About Alliance Pharma Stock (LON:APH)

Key Stats

Today's Range
44.60
45.10
50-Day Range
35.80
46.20
52-Week Range
24.55
47.95
Volume
619,744 shs
Average Volume
1.58 million shs
Market Capitalization
£243.26 million
P/E Ratio
N/A
Dividend Yield
4.44%
Price Target
GBX 60
Consensus Rating
Buy

Company Overview

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. The company also offers medicines, medical devices, food supplements, and cosmetics. It provides its products under the Aloclair, Anbesol, Asthon and Parsons, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. Alliance Pharma plc was incorporated in 1996 and is headquartered in Chippenham, the United Kingdom.

Alliance Pharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
53rd Percentile Overall Score

APH MarketRank™: 

Alliance Pharma scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alliance Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alliance Pharma has received no research coverage in the past 90 days.

  • Read more about Alliance Pharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alliance Pharma is -750.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alliance Pharma is -750.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Alliance Pharma has a PEG Ratio of 1.04. PEG Ratios around 1 indicate that a company is correctly valued.

  • Price to Book Value per Share Ratio

    Alliance Pharma has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for APH.
  • Dividend Leadership

    Alliance Pharma is a leading dividend payer. It pays a dividend yield of 3.75%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Alliance Pharma does not have a long track record of dividend growth.

  • Read more about Alliance Pharma's dividend.
  • Short Interest

    There is no current short interest data available for APH.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Alliance Pharma this week, compared to 0 articles on an average week.
  • Search Interest

    23 people have searched for APH on MarketBeat in the last 30 days. This is an increase of 109% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alliance Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.95% of the stock of Alliance Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    66.34% of the stock of Alliance Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alliance Pharma's insider trading history.
Receive APH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alliance Pharma and its competitors with MarketBeat's FREE daily newsletter.

APH Stock News Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Half Year Trading Update
Alliance Pharma PLC (DVL.SG)
See More Headlines

APH Stock Analysis - Frequently Asked Questions

Alliance Pharma's stock was trading at GBX 40.50 at the start of the year. Since then, APH shares have increased by 11.1% and is now trading at GBX 45.
View the best growth stocks for 2024 here
.

Shares of APH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alliance Pharma investors own include boohoo group (BOO), BP (BP), Vodafone Group Public (VOD), Aviva (AV), Babcock International Group (BAB), BAE Systems (BA) and The Gym Group (GYM).

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Electronic Equipment
CIK
N/A
Fax
N/A
Employees
91,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 60
High Stock Price Target
GBX 60
Low Stock Price Target
GBX 60
Potential Upside/Downside
+33.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
£-33,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£183.15 million
Cash Flow
GBX 5.72 per share
Book Value
GBX 41 per share

Miscellaneous

Free Float
N/A
Market Cap
£243.26 million
Optionable
Not Optionable
Beta
0.67
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (LON:APH) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners